Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

ESMO open·2025

Same author

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

ESMO open·2023

Same author

Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.

European journal of cancer (Oxford, England : 1990)·2023

Same author

Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].

ESMO open·2022

Same author

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

ESMO open·2022

Same author

Correction to: <sup>18</sup>F-Fluciclovine (<sup>18</sup>F-FACBC) PET imaging of recurrent brain tumors.

European journal of nuclear medicine and molecular imaging·2019

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab for recurrent ependymoma.

R M Green¹, T F Cloughesy, R Stupp

¹Department of Neurology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, USA.

|November 18, 2009

Summary

Bevacizumab-containing regimens show high radiographic response rates in recurrent ependymoma patients. This suggests potential efficacy for this challenging central nervous system malignancy.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Related Experiment Videos

Last Updated: Jun 18, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Area of Science:

Neuro-oncology
Medical oncology
Clinical research

Background:

Ependymoma, a rare glioma comprising 5% of CNS malignancies, often recurs and is refractory to treatment.
Standard chemotherapy lacks definition for ependymoma, and prognosis at recurrence is poor.
Bevacizumab has shown promise in recurrent glioblastoma, suggesting potential utility in other gliomas.

Purpose of the Study:

To evaluate the efficacy of bevacizumab-containing regimens in adult patients with recurrent ependymoma.
To determine radiographic response, time to progression, and overall survival in this patient cohort.

Main Methods:

Retrospective analysis of 8 adult patients with recurrent ependymoma treated with bevacizumab-containing chemotherapy.
Radiographic response assessed using Macdonald criteria.
Time to progression (TTP) and overall survival (OS) calculated using the Kaplan-Meier method.

Main Results:

Six out of eight patients (75%) achieved a partial response, and one had stable disease for over 8 months.
Median TTP was 6.4 months, and median OS was 9.4 months.
Bevacizumab was administered alone or with cytotoxic agents like irinotecan, carboplatin, or temozolomide.

Conclusions:

Bevacizumab-containing regimens demonstrate a high radiographic response rate in recurrent ependymoma.
These findings support further investigation into bevacizumab for recurrent ependymoma.
A prospective clinical trial is warranted to confirm these results.